Immunome dips after launching $400 mln stock offering

Shares of biotech co Immunome IMNM.O fall 2% post-market to $22.19 as it seeks equity

Bothell, Washington-based IMNM commences $400 mln stock offering

IMNM shares closed up 15.7% at $22.64 on Mon after co said its experimental drug, varegacestat, met main goal in late-stage study for patients with a rare type of tumor

Leerink, J.P. Morgan, TD Cowen, Goldman and Guggenheim are joint bookrunners for the offering

With ~91.7 mln shares outstanding, co has ~$2.1 bln market cap

Through Mon, shares up 113% YTD

All 13 analysts rate shares "strong buy" or "buy"; median PT of $32 up from $22 a month ago, per LSEG data